Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma

Dr Claudio Cerchione - IRCCS, Meldola, Italy

$Carfilzomib-lenalidomide-dexamethasone in the management of lenalidomide-refractory multiple myeloma ( Dr Claudio Cerchione - IRCCS, Meldola, Italy )$

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients

Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and implications for patients ( Dr Mathew Krebs, Dr Santiago Viteri, Dr Shirish Gadgeel and Prof Byoung Chul Cho )

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma

Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R B-cell non-Hodgkin’s lymphoma ( Dr Nilanjan Ghosh - Atrium Health Levine Cancer Institute, Charlotte, USA )

Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma

Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA

$Efficacy and safety of tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma ( Dr Stephen Schuster - Perelman Center for Advanced Medicine, Philadelphia, USA )$

Medical and scientific days of The Institute of Oncology Bucharest 2021 : Steps to the Oncology of Tomorrow

Dr Laurentiu Simion - University of Medicine and Pharmacy, C Davilla Bucharest, Surgeon Institute of Oncology Bucharest

Medical and scientific days of The Institute of Oncology Bucharest 2021 : Steps to the Oncology of Tomorrow ( Dr Laurentiu Simion - University of Medicine and Pharmacy, C Davilla Bucharest, Surgeon Institute of Oncology Bucharest )

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia

Dr John Byrd - The Ohio State University, Columbus, USA

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukaemia ( Dr John Byrd - The Ohio State University, Columbus, USA )

Breast cancer roundup from ASCO 2021

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Breast cancer roundup from ASCO 2021 ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia

Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA

Phase II study of blinatumomab for MRD-positive B-cell acute lymphoblastic leukaemia ( Prof Nicholas Short - The University of Texas MD Anderson Cancer Center, Houston, USA )

EHA 2021: Latest in immunotherapy for R/R multiple myeloma

Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo

EHA 2021: Latest in immunotherapy for R/R multiple myeloma ( Prof Evangelos Terpos, Prof Heinz Ludwig, Prof Meral Beksac and Prof Michele Cavo )

OncoAlert and ecancer ASCO roundup - Day 4 and 5

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer ASCO roundup - Day 4 and 5 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL

Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control cohort in R/R FL ( Prof Paola Ghione - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer

Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer ( Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA )

More from ecancer